- Home
- DKI vs CHRS Comparison
DKI vs CHRS Comparison
Compare DKI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DKI
- CHRS
- Stock Information
- Founded
- DKI 2018
- CHRS 2010
- Country
- DKI Hong Kong
- CHRS United States
- Employees
- DKI N/A
- CHRS N/A
- Industry
- DKI
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DKI
- CHRS Health Care
- Exchange
- DKI Nasdaq
- CHRS Nasdaq
- Market Cap
- DKI 140.0M
- CHRS 159.2M
- IPO Year
- DKI 2025
- CHRS 2014
- Fundamental
- Price
- DKI $1.02
- CHRS $1.68
- Analyst Decision
- DKI
- CHRS Strong Buy
- Analyst Count
- DKI 0
- CHRS 4
- Target Price
- DKI N/A
- CHRS $4.51
- AVG Volume (30 Days)
- DKI 3.1M
- CHRS 1.3M
- Earning Date
- DKI 01-01-0001
- CHRS 11-05-2025
- Dividend Yield
- DKI N/A
- CHRS N/A
- EPS Growth
- DKI N/A
- CHRS N/A
- EPS
- DKI 26.19
- CHRS 1.55
- Revenue
- DKI $10,204,329.00
- CHRS $272,209,000.00
- Revenue This Year
- DKI N/A
- CHRS N/A
- Revenue Next Year
- DKI N/A
- CHRS $109.48
- P/E Ratio
- DKI $0.04
- CHRS $3.21
- Revenue Growth
- DKI 100.46
- CHRS 52.33
- 52 Week Low
- DKI $0.80
- CHRS $0.66
- 52 Week High
- DKI $15.00
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- DKI N/A
- CHRS 66.07
- Support Level
- DKI N/A
- CHRS $1.56
- Resistance Level
- DKI N/A
- CHRS $1.72
- Average True Range (ATR)
- DKI 0.00
- CHRS 0.12
- MACD
- DKI 0.00
- CHRS 0.00
- Stochastic Oscillator
- DKI 0.00
- CHRS 75.28
About DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.